| RESEARCH ARTICLE |
|
| Year : 2023 | Volume
: 55
| Issue : 4 | Page : 223-228 |
Citicoline on the Barthel Index: Severe and moderate brain injury
Mehdi Mahmoodkhani1, Bahram Aminmansour2, Mehdi Shafiei2, Mohammadreza Hasas3, Donya Sheibani Tehrani4
1 Department of Neurosurgery, School of Medicine, Neurosciences Research Center, Kashani Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Neurosurgery, School of Medicine, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Neurosurgery, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of IT, Shahid Beheshti University, Tehran, Iran
Correspondence Address:
Mohammadreza Hasas
Department of Neurosurgery, Isfahan University of Medical Sciences, Isfahan
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijp.ijp_570_21
INTRODUCTION: Traumatic brain injury (TBI) is a paramount factor in mortality and morbidity. The clinical trials conducted to investigate the efficacy of neuroprotective agents, such as citicoline, as a therapeutic alternative for TBI have presented divergent findings. Therefore, this study aimed to evaluate and compare citicoline's effect on the Barthel Index in patients with severe and moderate brain injury.
MATERIALS AND METHODS: The study is a randomized clinical trial. Patients in the case group (35 patients) were treated with citicoline and the control group (34 patients) received a placebo. Data were analyzed using SPSS 16 software.
RESULTS: The results showed that changes in the Glasgow Coma Scale, changes in quadriceps muscle force score, Barthel Index score changes, achieving the status without intubation, and spontaneous breathing in patients treated with citicoline were not a statistically significant difference in the two groups (P > 0.05).
CONCLUSION: Findings revealed that citicoline did not impact the recovery process of severe and moderate TBI patients.
[FULL TEXT] [PDF]*
|
